{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:17:54Z","timestamp":1792642674194,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009781","name":"Australian Centre for HIV and Hepatitis Virology Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1145977"],"award-info":[{"award-number":["1145977"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jhep.2024.05.025","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T15:53:42Z","timestamp":1716911622000},"page":"794-805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["CRISPR-Cas13b-mediated suppression of HBV replication and protein expression"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6770-3889","authenticated-orcid":false,"given":"Laura C.","family":"McCoullough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9551-8213","authenticated-orcid":false,"given":"Mohamed","family":"Fareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitina","family":"Sozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-7074","authenticated-orcid":false,"given":"Christina","family":"Makhlouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yianni","family":"Droungas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8036-459X","authenticated-orcid":false,"given":"Chee Leng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7219-6206","authenticated-orcid":false,"given":"Mina","family":"Takawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart A.","family":"Fabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-3308","authenticated-orcid":false,"given":"Colin W.","family":"Pouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Netter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian FJ.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta A.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-2664","authenticated-orcid":false,"given":"Margaret","family":"Littlejohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Revill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.05.025_bib1","first-page":"8","year":"2021","journal-title":"Progress report on HIV, viral hepatitis and sexually transmitted infections 2021: accountability for the global health sector strategies, 2016\u20132021: actions for impact"},{"key":"10.1016\/j.jhep.2024.05.025_bib2","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1038\/ctg.2016.46","article-title":"Treatment of hepatitis B: a concise review","volume":"7","author":"Rajbhandari","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhep.2024.05.025_bib3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/gut.2004.060327","article-title":"Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D","volume":"54","author":"Erhardt","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.05.025_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A\u00a0global scientific strategy to cure hepatitis B","volume":"1","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2024.05.025_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.14851","article-title":"HBV 2021: new therapeutic strategies against an old foe","volume":"41","author":"Roca Suarez","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.05.025_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12985-021-01589-x","article-title":"Functional cure for chronic hepatitis B: accessibility, durability, and prognosis","volume":"18","author":"Song","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.jhep.2024.05.025_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.16968","article-title":"Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels","volume":"56","author":"Hall","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.05.025_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jvh.13211","article-title":"Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B","volume":"27","author":"Papatheodoridi","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2024.05.025_bib9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg < 100 IU\/mL and negative HBV RNA have lower risk of virological relapse after\u00a0nucleos(t)ide analogues cessation","volume":"56","author":"Xie","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2024.05.025_bib10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.05.025_bib11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.26385","article-title":"Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles","volume":"58","author":"Lee","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.05.025_bib12","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.05.025_bib13","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.05.025_bib14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","article-title":"Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials","volume":"79","author":"Gane","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.05.025_bib15","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.05.025_bib16","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1016\/S0168-8278(22)02041-4","article-title":"Bepirovirsen, antisense oligonucleotide\u00a0(ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study","volume":"77","author":"You","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.05.025_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molcel.2015.10.008","article-title":"Discovery and functional characterization of diverse class 2 CRISPR-cas systems","volume":"60","author":"Shmakov","year":"2015","journal-title":"Mol Cel"},{"key":"10.1016\/j.jhep.2024.05.025_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jhep.2024.05.025_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.05.025_bib20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.molcel.2019.09.013","article-title":"Programmable inhibition and detection of RNA viruses using Cas13","volume":"76","author":"Freije","year":"2019","journal-title":"Mol Cel"},{"key":"10.1016\/j.jhep.2024.05.025_bib21","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1038\/s41467-021-24577-9","article-title":"Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance","volume":"12","author":"Fareh","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.05.025_bib22","doi-asserted-by":"crossref","first-page":"10054","DOI":"10.1128\/JVI.01293-16","article-title":"In\u00a0vitro studies show that sequence variability contributes to marked variation in hepatitis B virus replication, protein expression, and function observed across genotypes","volume":"90","author":"Sozzi","year":"2016","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2024.05.025_bib23","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/jmv.23328","article-title":"In\u00a0vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection","volume":"84","author":"Cabuang","year":"2012","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jhep.2024.05.025_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/jhep.2003.50012","article-title":"Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in\u00a0vitro","volume":"37","author":"Chen","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.05.025_bib25","article-title":"A\u00a0PCR assay to quantify patterns of HBV transcription","volume":"102","author":"D'Arienzo","year":"2019","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.jhep.2024.05.025_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.22295","article-title":"The antiviral drug selected hepatitis B virus rtA181T\/sW172 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound","volume":"48","author":"Warner","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.05.025_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hep.31720","article-title":"Characterization and application of precore\/core-related antigens in animal models of hepatitis B virus infection","volume":"74","author":"Hong","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.05.025_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/JVI.01695-20","article-title":"Characterization of hepatitis B precore\/core-related antigens","volume":"95","author":"Hong","year":"2021","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2024.05.025_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.virol.2010.12.034","article-title":"Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody","volume":"411","author":"Walsh","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2024.05.025_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/(SICI)1096-9071(199909)59:1<19::AID-JMV4>3.0.CO;2-B","article-title":"Immunoassay detection of hepatitis B surface antigen mutants","volume":"59","author":"Coleman","year":"1999","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jhep.2024.05.025_bib31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"1","author":"Cox","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jhep.2024.05.025_bib32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/viro.1997.8863","article-title":"Heterogeneity and common features of defective hepatitis B virus genomes derived from spliced pregenomic RNA","volume":"238","author":"Gunther","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2024.05.025_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virol.2019.11.001","article-title":"Analysis of the in\u00a0vitro replication phenotype of African hepatitis B virus (HBV) genotypes and subgenotypes present in Australia identifies marked differences in DNA and protein expression","volume":"540","author":"Bannister","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2024.05.025_bib34","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication","volume":"41","author":"Ladner","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2024.05.025_bib35","first-page":"13","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"3","author":"Yan","year":"2012","journal-title":"elife"},{"key":"10.1016\/j.jhep.2024.05.025_bib36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1128\/iai.30.2.607-611.1980","article-title":"PLC\/PRF\/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity","volume":"30","author":"Daemer","year":"1980","journal-title":"Infect Immun"},{"key":"10.1016\/j.jhep.2024.05.025_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102112","article-title":"Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in\u00a0vitro and in\u00a0vivo","volume":"35","author":"Smekalova","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhep.2024.05.025_bib38","first-page":"1652","article-title":"Efficient silencing of hepatitis B virus\u00a0S\u00a0gene\u00a0through CRISPR-mediated base editing","volume":"6","author":"Zhou","year":"2022","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2024.05.025_bib39","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1159\/000508568","article-title":"The burden and trends of primary liver cancer caused by specific etiologies from 1990 to 2017 at the global, regional, national, age, and sex level results from the global burden of disease study 2017","volume":"9","author":"Lin","year":"2020","journal-title":"Liver cancer"},{"key":"10.1016\/j.jhep.2024.05.025_bib40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.05.025_bib41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.05.025_bib42","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.05.025_bib43","first-page":"41","article-title":"Tenofovir-associated bone density loss","volume":"6","author":"Grigsby","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jhep.2024.05.025_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2019.07.015","article-title":"Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B","volume":"72","author":"Le Bert","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.05.025_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-8278(01)00264-1","article-title":"The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication","volume":"36","author":"Sobao","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.05.025_bib46","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.05.025_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-5793(03)00400-9","article-title":"Short interfering RNA-directed inhibition of hepatitis B virus replication","volume":"543","author":"Hamasaki","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhep.2024.05.025_bib48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3349\/ymj.1995.36.6.527","article-title":"Inhibition of HBV replication by antisense oligodeoxyribonucleotides in HepG2 cells transfected with a cloned HBV DNA","volume":"36","author":"Oh","year":"1995","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jhep.2024.05.025_bib49","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbrc.2003.08.021","article-title":"Selective inhibition of hepatitis B virus replication by RNA interference","volume":"309","author":"Ying","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2024.05.025_bib50","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpdd.1154","volume":"11","author":"Han","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jhep.2024.05.025_bib51","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.05.025_bib52","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1525-0016(03)00244-2","article-title":"Small interfering RNA inhibits hepatitis B virus replication in mice","volume":"8","author":"Giladi","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2024.05.025_bib53","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1089\/10430349950017734","article-title":"High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA","volume":"10","author":"Zhang","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhep.2024.05.025_bib54","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"1","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.05.025_bib55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"1","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.05.025_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in\u00a0vivo genome editing of Angptl3","volume":"118","author":"Qiu","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2024.05.025_bib57","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41589-022-01094-4","article-title":"Cas13d knockdown of lung protease Ctsl\u00a0prevents and treats SARS-CoV-2 infection","volume":"18","author":"Cui","year":"2022","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jhep.2024.05.025_bib58","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2024.05.025_bib59","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent inactivation of HBV genomes by CRISPR\/Cas9-Mediated non-cleavage base editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782400360X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782400360X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:59:10Z","timestamp":1773457150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782400360X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S016882782400360X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.05.025","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR-Cas13b-mediated suppression of HBV replication and protein expression","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}